BOLT logo

BOLT BIOTHERAPEUTICS INC

BOLTNASDAQ
πŸ† #4686 by market capEarnings Mar 11US Equity
$4.91β–Ό $0.15 (βˆ’2.96%)
Market closed Β· at close
πŸ””
Track BOLT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 3.0%
7dβ–Ό 19.3%
14dβ–Ό 24.7%
30dβ–Ό 21.5%
ytdβ–Ό 9.2%
1yβ–² 2.7%
🏦Market Cap
$13M
Small Cap
πŸ“ˆRevenue Growth (YoY)
12.8%
Healthy
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
2.7x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$4.88 – $5.21
52-Week Range
$3.10 – $7.78
Volume (shares)
60,491
Avg Volume (shares)
β€”
Shares Outstanding
2.6M
Next Earnings
2027-03-11

Fundamentals Snapshot

Annual Revenue
$8M
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
2.7x
EPS (TTM)
$-16.44
Dividend Yield
β€”
Dilution (1yr)
βˆ’2.3%
BOLT logo

BOLT BIOTHERAPEUTICS INC

BOLT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$8Mβ–² +0.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
80.6%β–Ό βˆ’19.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$35Mβ–Ό βˆ’52.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$40Mβ–Ό βˆ’34.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.9Mβ–Ό βˆ’2.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$11Mβ–² +$7M YoY
StockOtter Β· stockotter.space

About BOLT BIOTHERAPEUTICS INC

Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy2
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

GlobeNewsWireΒ·10d ago

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt's primary development focus Initiated Phase 2 studies with PRA

GlobeNewsWireΒ·18d ago

INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action AttorneyΒ  Juan Monteverde with Monteverde & Associates PC (the β€œM&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a

PRNewsWireΒ·19d ago

INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?

/PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for

GlobeNewsWireΒ·19d ago

Bolt Biotherapeutics to Participate in Upcoming Conferences

REDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (β€œBolt” or the β€œCompany”), a clinical-stage biotechnology company pioneering a new generation of half-life-extended multis

Seeking AlphaΒ·27d ago

Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript

Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript

PRNewsWireΒ·27d ago

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)

NEW YORK, Oct. 26, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC Β (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top